SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : NexStar Pharm(NXTR)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Chris Boylan who wrote (323)3/4/1999 1:27:00 PM
From: Biomaven  Read Replies (1) of 328
 
Chris,

If PREVEON gets approved who is going to use it?

Don't forget the excellent results they had for it with Hepatitis B.

GILD's 'flu efficacy looks better than Glaxo's (although it is always hard to compare across different trials) and the Glaxo AC seemed pretty open to a flu drug that has demonstrated efficacy.

I wonder if the long-standing huge NXTR short position is adding to the surge in GILD/NXTR today? Unless these shorts are already boxed against the old convertible, they will have to cover in either NXTR or GILD shares.

I do agree that GILD is quite a different sort of company than NXTR, with quite different risk/rewards.

Peter
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News